Research location
Jaú
São Paulo, Brazil
Advertisement
Research activity in Jaú
São Paulo, BrazilCureCurrent currently publishes aggregate city-level research activity for this location: 58 trials and 61 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Jaú
58 linked trials · page 2 of 2A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.NCT00451906 · 2006-08-01 · 1 site observation
COMPLETED
EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast CancerNCT00338247 · 2006-07-01 · 1 site observation
APPROVED_FOR_MARKETING
A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.NCT00545688 · 2006-06-26 · 1 site observation
COMPLETED
A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)NCT00300885 · 2006-02-01 · 1 site observation
TERMINATED
Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2NCT00281658 · 2006-01-02 · 1 site observation
COMPLETED
Randomized Trial of Gemcitabine/Cisplatin + PF-3512676 vs Gemcitabine/Cisplatin Alone in Patients With Advanced NSCLCNCT00254904 · 2005-11-01 · 2 site observations
TERMINATED
Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast CancerNCT00080301 · 2003-09-01 · 1 site observation
COMPLETED
Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic RegimenNCT02475382 · 1 site observation
NO_LONGER_AVAILABLE
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.